What is the recommended starting dose of Entresto (sacubitril/valsartan) for a 50‑kg adult female with no contraindications who is ACE‑inhibitor/ARB naïve or on a low dose?

Entresto Dosing for a 50‑kg Adult Female

For a 50‑kg adult female with no contraindications who is ACE‑inhibitor/ARB naïve or on a low dose, start Entresto (sacubitril/valsartan) at 24 mg/26 mg twice daily, then titrate to 49 mg/51 mg twice daily after 2 weeks, and finally to the target maintenance dose of 97 mg/103 mg twice daily after another 2–4 weeks as tolerated. 1

Standard Adult Dosing Algorithm

• Patients NOT currently on an ACE inhibitor or ARB, or previously on LOW doses: Begin at half the usual starting dose (24 mg/26 mg twice daily), then double every 2–4 weeks to reach 49 mg/51 mg, and finally 97 mg/103 mg twice daily. 1

• Patients already on moderate‑to‑high doses of ACE inhibitor or ARB: Start at the standard dose of 49 mg/51 mg twice daily, then increase to the target of 97 mg/103 mg twice daily after 2–4 weeks. 1

• Mandatory washout period: If switching from an ACE inhibitor, allow a 36‑hour washout before initiating Entresto to avoid angioedema risk. 1

Weight‑Based Considerations

• Although your patient weighs 50 kg, the FDA label does not require weight‑based dose adjustment in adults; the standard adult dosing schedule applies regardless of body weight. 1

• Weight‑based dosing (mg/kg) is reserved for pediatric patients aged 1 year and older; for a pediatric patient weighing exactly 50 kg, the starting dose would be 49 mg/51 mg twice daily (same as the standard adult starting dose for those on prior RAAS inhibition). 1

Titration and Monitoring

• Titration schedule: Increase the dose every 2–4 weeks in adults, monitoring blood pressure, renal function (serum creatinine/eGFR), and potassium at each step. 1

• Target dose: The goal is 97 mg/103 mg twice daily, which was the dose proven to reduce cardiovascular death and heart‑failure hospitalization in the PARADIGM‑HF trial. 2, 3

• Hypotension management: Symptomatic hypotension is more common with Entresto than with ACE inhibitors; if it occurs, consider reducing concomitant diuretics or temporarily lowering the Entresto dose before re‑attempting titration. 2, 3

Special Dosing Adjustments (If Applicable)

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²): Start at half the usual starting dose (24 mg/26 mg twice daily), then follow the standard escalation schedule. 1

• Moderate hepatic impairment (Child‑Pugh B): Start at half the usual starting dose (24 mg/26 mg twice daily), then titrate as tolerated. 1

• No dose adjustment is needed for mild‑to‑moderate renal impairment or mild hepatic impairment. 1

Critical Safety Precautions

• Contraindications: Do not use Entresto concomitantly with ACE inhibitors (36‑hour washout required), in patients with a history of angioedema related to prior ACE inhibitor or ARB therapy, or during pregnancy (causes fetal toxicity). 1, 2

• Monitoring for angioedema: Although the incidence is low, angioedema can occur; educate the patient to seek immediate care if facial, lip, or tongue swelling develops. 2, 3

• Hyperkalemia and renal function: Check potassium and creatinine within 1–2 weeks of initiation or dose increase, especially in patients with chronic kidney disease or diabetes. 1

Evidence Supporting Superior Efficacy

• In the PARADIGM‑HF trial, sacubitril/valsartan reduced the composite primary endpoint of cardiovascular death or heart‑failure hospitalization by 20% compared with enalapril, and reduced all‑cause mortality significantly. 2, 3

• Sacubitril/valsartan provides dual neurohormonal modulation by enhancing the natriuretic peptide system (via neprilysin inhibition) and suppressing the renin‑angiotensin system (via AT1 receptor blockade), making it superior to ACE inhibitors or ARBs alone. 3

• A 2024 meta‑analysis confirmed that sacubitril/valsartan is superior to sub‑equivalent doses of ACE inhibitors or ARBs, but shows no additional benefit when compared to equivalent doses (e.g., enalapril 20 mg twice daily or valsartan 160 mg twice daily). 4

Common Pitfalls to Avoid

• Do not delay titration: Many patients remain on suboptimal doses in clinical practice; aim to reach the target dose of 97 mg/103 mg twice daily within 4–8 weeks unless hypotension or renal dysfunction limits escalation. 1, 2

• Do not combine with ACE inhibitors or ARBs: Dual RAAS blockade increases the risk of hyperkalemia, hypotension, and renal dysfunction without added benefit. 1, 3

• Do not assume weight‑based dosing in adults: The 50‑kg body weight does not trigger pediatric dosing rules; use the standard adult algorithm. 1